November 13, 2017 05:30 AM EST

J&J antes $50M to get Zymeworks' 6th big bispecifics alliance underway, with $6B in total milestones on the table

John Carroll

Editor & Founder

Newly public Zymeworks $ZYME has just lined up its 6th major biopharma discovery alliance, this time bringing J&J $JNJ into a fold that already includes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J antes $50M to get Zymeworks' 6th big bispecifics alliance underway, with $6B in total milestones on the table

John Carroll

Editor & Founder

Sign up to read this article for free.

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

J&J antes $50M to get Zymework­s' 6th big bis­pecifics al­liance un­der­way, with $6B in to­tal mile­stones on the ta­ble

John Carroll

Editor & Founder

Sign up to read this article for free.

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

J&J antes $50M to get Zymeworks' 6th big bispecifics alliance underway, with $6B in total milestones on the table

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development